Vagus nerve stimulation (VNS) devices modulate heart rate through a well-characterised pathway: electrical activation of vagal efferent fibres triggers acetylcholine release at cardiac nerve terminals, which binds M2 muscarinic receptors on pacemaker cells in the sinoatrial and atrioventricular nodes, slowing both heart rate and conduction velocity. This cardiac effect is not a side effect but the therapeutic target in an emerging field of bioelectronic medicine that aims to treat heart failure by restoring autonomic balance. Understanding how VNS interacts with cardiac rhythm is essential both for patients using epilepsy-approved devices and for evaluating the cardiac applications now in clinical trials.
Left vs Right Vagus: Cardiac Asymmetry
The left and right vagus nerves differ in their cardiac innervation, and this asymmetry is clinically significant. The right vagus nerve predominantly innervates the sinoatrial (SA) node, making it the stronger chronotropic modulator. Stimulating the right vagus produces more pronounced heart rate slowing. The left vagus nerve preferentially innervates the atrioventricular (AV) node, where it slows conduction velocity with less effect on resting heart rate.
This is why VNS for epilepsy is implanted on the left cervical vagus. The anti-seizure effect requires afferent stimulation reaching the brainstem, and either side delivers that equally. But the left side minimises the cardiac chronotropic effect, reducing the risk of clinically significant bradycardia. In cardiac applications where slowing heart rate is the goal, right-sided or bilateral stimulation becomes more relevant.
The ANTHEM-HFrEF Trial
The most ambitious clinical test of VNS for heart disease was the ANTHEM-HFrEF trial, sponsored by LivaNova. The trial enrolled 532 patients with heart failure with reduced ejection fraction (mean LVEF approximately 26 percent, mostly NYHA class III) and randomised them to VNS plus guideline-directed medical therapy (GDMT) versus GDMT alone. The planned sample size was 1,000, but the sponsor terminated the trial early for financial reasons.
The primary endpoint, time to cardiovascular death or heart failure hospitalisation over approximately 3.5 years, showed no statistically significant benefit for VNS (hazard ratio 0.84, 95 percent CI 0.63 to 1.13). However, quality-of-life improvements measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) were significantly greater in the VNS group at 9 months (13.1 vs 7.5 point improvement, one-sided p less than 0.001). The adjudicated device-related serious adverse event rate at 90 days was 3.5 percent.
The premature termination makes definitive conclusions impossible. The quality-of-life signal is notable because KCCQ changes of this magnitude are clinically meaningful, but without the planned sample size, the hard-endpoint question remains unanswered. Whether VNS for heart failure will be revisited likely depends on whether closed-loop or optimised dosing protocols can strengthen the cardiac signal.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- HRV biofeedback
- Polyvagal-informed therapy
- Somatic therapy
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
How VNS Alters Heart Rate Dynamics
Beyond simple rate slowing, VNS changes the pattern of heart rate variability (HRV). In heart failure, vagal withdrawal produces low HRV, a condition associated with increased mortality. VNS has been shown to restore the high-frequency (HF) component of HRV, which reflects cardiac parasympathetic modulation. This shift from sympathetic dominance toward parasympathetic engagement represents a rebalancing of the autonomic nervous system.
The mechanism involves more than direct cardiac effects. Vagal affeents activated by VNS reach the NTS, which projects to the dorsal motor nucleus of the vagus (efferent cardiac output) and to the rostral ventrolateral medulla (which modulates sympathetic outflow). VNS therefore simultaneously enhances parasympathetic tone and dampens sympathetic overdrive, producing a dual autonomic correction.
Heart rate itself serves as a biomarker of adequate VNS delivery. During implantation and programming, clinicians look for a transient heart rate decrease of 5 to 10 percent during stimulation as confirmation that the electrode is properly positioned and the current is reaching vagal fibres.
Non-Invasive tVNS and Cardiac Effects
Transcutaneous VNS (tVNS) applied to the auricular branch of the vagus nerve (ABVN) at the tragus also produces measurable cardiac effects, though they are milder than implanted VNS. Studies show that acute tragal tVNS can increase the HF-HRV component and modestly reduce resting heart rate. Research published in Arrhythmia and Electrophysiology Review has demonstrated that tVNS improves sympathovagal balance in conditions characterised by autonomic dysfunction, including postural orthostatic tachycardia syndrome (POTS), where it may help reduce the excessive heart rate increase upon standing.
The anti-inflammatory properties of vagal stimulation also have cardiac relevance. The cholinergic anti-inflammatory pathway, activated by vagal efferents reaching the spleen via the celiac ganglion, reduces production of TNF-alpha and other pro-inflammatory cytokines. Since inflammation plays a role in heart failure progression and post-myocardial infarction remodelling, this provides a second therapeutic mechanism beyond direct autonomic modulation.
Safety Considerations
For patients with epilepsy VNS devices, clinically significant cardiac effects are uncommon when the left vagus is stimulated at standard parameters. Asystole during lead testing at implantation occurs in approximately 0.1 percent of cases and resolves immediately when stimulation stops. Routine ECG monitoring during initial programming is standard practice.
Patients with pre-existing cardiac conduction abnormalities, those on beta-blockers or calcium channel blockers, and those with bradycardia below 50 bpm require careful assessment before VNS implantation. The combination of VNS-induced vagal enhancement with pharmacological rate-slowing agents can occasionally produce additive effects.
Want to understand how the vagus nerve regulates your heart and why that matters for conditions from arrhythmia to heart failure? Get My Vagus Nerve & Me eBook for a clear guide to the science behind vagal cardiac control.
